Results 51 to 60 of about 284,370 (314)
European Journal of Breast Health, 2022 Objective:Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy ...
Damiano Gentile +8 more
doaj +1 more source
Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]
, 2017 Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia +5 more
core +1 more source
Epidemiological and pathological characteristics of postsurgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study [PDF]
Archive of Oncology, 2020 Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of ...
Sayad Soheila +4 more
doaj
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
Exploration of Targeted Anti-tumor Therapy, 2021 About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene.
Paolo Tarantino +2 more
doaj +1 more source
Current perspective - Trastuzumab [PDF]
, 2009 This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast ...
Cameron, D.A., Hall, P.S.
core +1 more source
陆军军医大学学报, 2022 Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation ...
LIN Qingyue, QU Jingjing, ZHOU Jianying
doaj +1 more source
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention [PDF]
, 2016 The ErbB/B2 (HER-2/neu) oncogene family plays a critical role in the development and metastatic spread of several tumor types including breast, ovarian and gastric cancer.
Czerniecki, Brian J. +4 more
core +2 more sources
[Anti-HER2 vaccines: The HER2 immunotargeting future?].
Pathologie-biologie, 2009 Breast cancer is a widely spread women's disease. In spite of progress in the field of surgery and adjuvant therapies, the risk of breast cancer metastatic relapses remains high especially in those overexpressing HER2. Different studies have shown cellular and/or humoral immune responses against HER2 in patients with HER2-overexpressing tumors.
Ladjemi, Maha-Zohra +3 more
openaire +2 more sources
Libyan Journal of Medicine, 2021 Aim: Colorectal cancer (CRC) is one of the leading cancers in the world. Even though its mortality and pathophysiology are well documented in the US and the European countries, it is seldom studied in North African population.
Eman A. Abdul Razzaq +9 more
doaj +1 more source
hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. [PDF]
, 2015 Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 ...
Circo, R +11 more
core +2 more sources